<DOC>
	<DOCNO>NCT01571661</DOCNO>
	<brief_summary>This double blind , randomise , placebo control , single dose escalation , first-time-in-human , 5-way crossover study ass safety , tolerability , pharmacokinetic pharmacodynamic parameter ascend dos GSK189075A healthy subject ( Part A ) . Single dose give 10 healthy subject . The planned dos 20mg , 50mg , 150mg , 500mg , 1000mg . Each subject receive 4 5 active dos placebo separate washout 5-10 day . A second cohort 6 subject type 2 diabetes mellitus receive 2 active dos placebo along oral glucose three-way , randomise , placebo control , crossover design ass glucose lower follow GSK189075A administration ( Part B ) . Blood sample take throughout study day pharmacokinetic analysis prodrug metabolite . Safety assess measurement blood glucose , blood pressure , heart rate , ECGs , laboratory safety screen , collection adverse event .</brief_summary>
	<brief_title>A First-time-in-human Study Assess Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Ascending Doses GSK189075A Healthy Subjects Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Women must nonchildbearing potential . Nonchildbearing potential define : Postmenopausal female define amenorrhoeic great one year appropriate clinical profile , e.g. , age appropriate , history vasomotor symptom . However , indicate , confirm estradiol FSH level consistent menopause ( accord local laboratory range ) Premenopausal female document ( medical report verification ) hysterectomy tubal ligation . A negative prestudy urine drug screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . Negative result hepatitis C antibody , hepatitis B surface antigen HIV screening , document negative test result within last 6 month . Signed date write informed consent prior admission study . The subject able understand comply protocol requirement , instruction protocolstated restriction . Subjects follow clinical laboratory value : ALT AST &lt; 2 time upper limit normal screen prior first dose ; fast triglyceride &lt; 400mg/dL screen prior first dose ; bilirubin &lt; 1.5 time upper limit normal screen prior first dose ( total ; subject limit may include direct bilirubin within normal limit ) . Other value must within normal range clinically significant screen checkin . Abnormal value , deem clinically significant principal investigator , must clear medical monitor GSK . Additional inclusion criterion subject Part A : A subject eligible inclusion Part A study follow criterion apply : Healthy adult subject age 18 55 year inclusive , male female subject nonchildbearing potential . Body weight great equal 50kg men great equal 45kg woman BMI within range 19.0 30.0kg/m2 inclusive . Healthy judge responsible physician . No clinically significant abnormality identify medical laboratory evaluation , include 12lead ECG . A subject clinically significant abnormality , laboratory parameter outside reference range age group may include Investigator Sponsor 's Medical Monitor consider find introduce additional risk factor interfere study procedure . Part B : A subject eligible inclusion Part B study follow criterion meet : Subjects document type 2 diabetes mellitus diagnosis ( diagnose less 6 month ; HbA1c le equal 10 % FPG &lt; 280 mg/dL screening ) either control diet alone monotherapy minimum 3 month either oral sulfonylurea , rosiglitazone , metformin , acarbose . They must willing/able discontinue medication dose occasion 72 hour ( checkin research unit release last study assessment dose period ) . Adult men woman 30 60 year inclusive . Women must nonchildbearing potential . BMI within range 22 35kg/m2 inclusive . Subjects take stable regimen medication commonly use prevention diabetic ( aspirin , ACE inhibitor , statin ) allow dose regimen ( ) remain constant throughout study period . Concurrent usage prescribe medication medication list may allow continue Sponsor 's consent . No significant concomitant health problem type 2 diabetes mellitus otherwise healthy judge responsible physician . Systolic/Diastolic blood pressure : great equal 80/60 mmHg less equal 150/95 mmHg screening . History presence allergy study drug drug class history drug allergy , opinion physician responsible , contraindicate participation . History presence gastrointestinal , hepatic renal disease , condition know interfere absorption , distribution , metabolism excretion drug . Any acute gastrointestinal illness within 2 week prior dose . Use diuretic , systemic corticosteroid , medication may result electrolyte depletion , within 3 week schedule dose . Blood electrolyte ( K , Na , Cl , Mg Ca bicarbonate ) value outside reference range screen admission . No deviation permit unless discussion individual basis sponsor investigator follow parameter : sodium , potassium , chloride , bicarbonate , calcium magnesium . If participation study result subject donate 1,500mL blood ( male ) 1,000mL ( female ) previous 12 month 6. participation study would result donation blood excess 550mL within 56day period . As result medical interview , physical examination screen investigation , Physician Responsible considers volunteer unfit study . They suffer urinary tract bladder infection within 4 week start study . Abuse alcohol Significant renal disease Any clinically significant abnormality identify medical laboratory evaluation , include 12lead ECG 24 h Holter monitoring . A subject clinically significant abnormality laboratory parameter outside reference range age group may include Investigator Sponsor 's Medical Monitor consider find introduce additional risk factor interfere study procedure Participation study trial drug new chemical entity within 90 day prior start study . Male subject unwilling abstain , use condom sexual intercourse pregnant lactate female ; male subject unwilling use condom plus another form contraception ( e.g. , spermicide , IUD , birth control pills take female partner , diaphragm spermicide ) sexual intercourse female could become pregnant . Any male subject unwilling adhere contraceptive criterion administration study medication completion followup procedure . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication release last study assessment last dosing period , unless opinion Investigator Sponsor medication interfere study procedure compromise subject safety . Part A : A subject eligible inclusion Part A study follow applies : Past present disease , judge Investigator , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease , haematological disease , neurological disease endocrine disease . Part B : A subject eligible inclusion Part A study follow criterion apply : Currently require insulin therapy , insulin therapy previous 3 month prior screen examination . Medically unable unwilling discontinue oral antidiabetic medication 72 hour ( checkin research unit release last study assessment dose period ) . Past present disease ( type 2 diabetes mellitus ) judge Investigator , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease , haematological disease , neurological disease endocrine disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>KGT-1142</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>single-dose escalation</keyword>
	<keyword>tolerability</keyword>
</DOC>